BioSpace News Archive

Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease Type C (NPC).

Today the U.S. Food and Drug Administration permitted marketing of ClonoSEQ assay, a next generation sequencing (NGS)-based test for minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) or multiple myeloma. MRD is a measure of the amount of cancer cells remaining in a person’s bone marrow.

Approval allows use of therascreen® EGFR RGQ PCR Kit as a companion diagnostic for Pfizer’s VIZIMPRO® (dacomitinib) in patients with non-small cell lung cancer

Alnylam Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis.

TransThera Biosciences Co. Ltd, announced today that the company received FDA IND application approval for TT-00420, a novel small molecule investigational drug targeting Triple-Negative Breast Cancer (TNBC).

CEL-SCI Corporation is advising the holders of its publicly traded warrants (NYSE American: CVM WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 11, 2018.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a presentation and host one-on-one meetings with investors at the 2018 Cantor Fitzgerald Global Healthcare Conference at the Intercontinental NY Barclay Hotel.

Zoetis (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 1, 2018.

Illumina, Inc.. (Nasdaq: ILMN) (“Illumina” or the “Company”) today notified holders of its 0% Convertible Senior Notes due 2019 (the “2019 Notes”) and its 0.5% Convertible Senior Notes due 2021 (the “2021 Notes” and, together with the 2019 Notes, the “Notes”) that the Notes will become convertible into Illumina common stock at the option of the holders (the “Conversion Option”) beginning on October 1, 2018, and ending at the close of business on December 31, 2018.

Injured veterans and guests used state-of-the-art laser guns to simulate an energy-charged combat mission during a recent Wounded Warrior Project® (WWP) connection event.